Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn’s disease
Frontiers in Nutrition · 20.05.2026 · 13
DOI: 10.3389/fnut.2026.1825135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 20.05.2026. Verfasst von Hanyu Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ustekinumab (UST) has emerged as an effective biological therapy for Crohn’s disease (CD), yet many patients experience suboptimal long-term mucosal healing. Partial enteral nutrition (PEN) may enhance treatment outcomes by reducing intestinal inflammation and improving nutritional status. However, evidence regarding the combined use of UST and PEN remains limited. This study aims to investigate the effect of UST combined with PEN on therapeutic efficacy in CD patients.
Methods
We conducted a single-center, retrospective cohort study including adult CD patients who received UST induction and maintenance therapy. Patients were stratified into a UST + PEN group and a UST monotherapy group according to whether ≥50% of their calculated daily energy intake was provided by PEN. Clinical outcomes (CDAI at weeks 8 and 24) and the primary endpoint endoscopic remission at week 54 (SES-CD < 3 without ulcers) were assessed. Multivariable logistic regression was used to identify independent predictors of endoscopic remission.
Results
A total of 124 patients were included, with 38 receiving UST + PEN. Despite having lower BMI and higher baseline CDAI, the endoscopic remission rate at week 54 was significantly higher in the combination group (71.05% vs. 50.00%, p = 0.029). Multivariable analysis demonstrated that combining PEN with UST was an independent protective factor for endoscopic remission [OR 2.84 (95% CI 1.11–7.26), p = 0.0289]. Subgroup analyses showed consistent benefit across demographic and disease-related subgroups.
Conclusion
Ustekinumab combined with partial enteral nutrition is associated with higher rates of endoscopic remission at week 54 in patients with Crohn’s disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Department of Gastroenterology, Xianju County People's Hospital, Xianju, Zhejiang, China.
Zitieren
APA
Yin, H., Chen, C., Chen, X., Yao, W., Huang, C., Chen, J., Zhu, M., & Wu, X. (2026). Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn’s disease. Frontiers in Nutrition, 13. https://doi.org/10.3389/fnut.2026.1825135
Vancouver
Yin H, Chen C, Chen X, Yao W, Huang C, Chen J, et al. Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn’s disease. Frontiers in Nutrition. 2026;13. doi:10.3389/fnut.2026.1825135
BibTeX
@article{Yin2026,
author = {Yin, Hanyu and Chen, Chao and Chen, Xiaowei and Yao, Weixiang and Huang, Chen and Chen, Jiahe and Zhu, Mengying and Wu, Xiaoli},
title = {Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn’s disease},
journal = {Frontiers in Nutrition},
year = {2026},
volume = {13},
doi = {10.3389/fnut.2026.1825135}
}
EUVIMED